## CITATION REPORT List of articles citing

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

DOI: 10.1016/j.eursup.2008.08.002 European Urology Supplements, 2008, 7, 618-626.

Source: https://exaly.com/paper-pdf/44137856/citation-report.pdf

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
78	Role and rationale of gene therapy and other novel therapies in the management of NMIBC. <i>Expert Review of Anticancer Therapy</i> , <b>2009</b> , 9, 1777-82	3.5	2
77	Strategies to improve drug delivery in bladder cancer therapy. <i>Expert Opinion on Drug Delivery</i> , <b>2009</b> , 6, 727-44	8	14
76	Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. <i>European Urology</i> , <b>2009</b> , 56, 430-42	10.2	466
75	Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2028-34	3.1	41
74	Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population?. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , <b>2009</b> , 680, 56-63	3	49
73	Recurrence, Progression, and Follow-Up in NonâMuscle-Invasive Bladder Cancer. <i>European Urology Supplements</i> , <b>2009</b> , 8, 556-562	0.9	38
<del>7</del> 2	Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 3068-75	3.1	26
71	Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. <i>Journal of Controlled Release</i> , <b>2010</b> , 148, 147-59	11.7	172
70	Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. <i>DNA and Cell Biology</i> , <b>2010</b> , 29, 349-56	3.6	18
69	TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. <i>Folia Histochemica Et Cytobiologica</i> , <b>2009</b> , 47, 579-85	1.4	28
68	Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. <i>Urology</i> , <b>2010</b> , 76, 765.e1-7	1.6	27
67	Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. <i>European Journal of Surgical Oncology</i> , <b>2011</b> , 37, 727-33	3.6	23
66	Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. <i>Surgery</i> , <b>2011</b> , 149, 126-34	3.6	28
65	The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gufin: external validation of the EORTC risk tables. <i>European Urology</i> , <b>2011</b> , 60, 423-30	10.2	121
64	Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. <i>World Journal of Urology</i> , <b>2011</b> , 29, 517-21	4	28
63	Association of p53 codon 248 (exon7) with urinary bladder cancer risk in the North Indian population. <i>BioScience Trends</i> , <b>2011</b> , 5, 205-10	9.9	8
62	Branched peptides as novel tumor-targeting agents for bladder cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 699-701	3.5	7

61	Down-staging (. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, <b>2012</b> , 461, 149-56	5.1	6
60	Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2012</b> , 30, 518-23	2.8	28
59	Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian population. <i>Molecular Biology Reports</i> , <b>2012</b> , 39, 9827-34	2.8	12
58	Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. <i>Molecular Biology Reports</i> , <b>2012</b> , 39, 5615-21	2.8	30
57	Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in North Indian population. <i>Mechanisms of Ageing and Development</i> , <b>2012</b> , 133, 127-32	5.6	48
56	The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , <b>2014</b> , 32, 651-9	4	17
55	Primary prevention and early detection of bladder cancer: two main goals for urologists. <i>European Urology</i> , <b>2013</b> , 63, 242-3	10.2	10
54	Comparison of surveillance strategies for low-risk bladder cancer patients. <i>Medical Decision Making</i> , <b>2013</b> , 33, 198-214	2.5	8
53	Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. <i>Gene</i> , <b>2013</b> , 519, 128-34	3.8	39
52	Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 247-54	2.8	29
51	Bladder cancer biorepositories in the "-omics" era: integrating quality tissue specimens with comprehensive clinical annotation. <i>Biopreservation and Biobanking</i> , <b>2013</b> , 11, 166-72	2.1	4
50	Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. <i>Urology</i> , <b>2013</b> , 81, 277-81	1.6	14
49	Analysis of radical cystectomy and urinary diversion complications with the Clavien classification system in an Italian real life cohort. <i>European Journal of Surgical Oncology</i> , <b>2013</b> , 39, 792-8	3.6	58
48	Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors. <i>Health and Quality of Life Outcomes</i> , <b>2013</b> , 11, 43	3	52
47	Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk. <i>Medical Oncology</i> , <b>2013</b> , 30, 509	3.7	15
46	Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population. <i>Archives of Medical Research</i> , <b>2013</b> , 44, 54-61	6.6	36
45	[Epidemiology of disease conditions in Italy. Has anything changed? Environment, professional exposure, and lifestyle. Is time for screening?]. <i>Urologia</i> , <b>2013</b> , 80 Suppl 21, 3-6	1.2	
44	Replicative study of GWAS TP63C/T, TERTC/T, and SLC14A1C/T with susceptibility to bladder cancer in North Indians. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1209-14	2.8	16

43	Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer?. <i>Cancer Epidemiology</i> , <b>2014</b> , 38, 157-61	2.8	12
42	Transuretral resection of the bladder (TURB): analysis of complications using a modified Clavien system in an Italian real life cohort. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 90-5	3.6	33
41	Impact of chemokines CCR5âB2, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population. <i>Tumor Biology</i> , <b>2014</b> , 35, 4765-72	2.9	7
40	Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population. <i>Molecular Biology Reports</i> , <b>2014</b> , 41, 799-807	2.8	16
39	Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis. <i>Tumor Biology</i> , <b>2014</b> , 35, 6415-23	2.9	4
38	Animal models of urinary bladder cancer and their application to novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , <b>2014</b> , 9, 485-503	6.2	8
37	Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients. <i>Oncology Letters</i> , <b>2014</b> , 8, 1447-1454	2.6	6
36	O papel da ressonficia magntica em doentes com tumor vesical. Acta Urolgica Portuguesa, 2015,	O	
35	New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. <i>Korean Journal of Urology</i> , <b>2015</b> , 56, 553-64		8
34	Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. <i>BioMed Research International</i> , <b>2015</b> , 2015, 168682	3	31
33	World Urologic Oncology Federation Bladder Cancer Prevention Program: a global initiative. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 25-29	2.8	24
32	CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. <i>Molecular Carcinogenesis</i> , <b>2015</b> , 54, 1451-66	5	48
31	External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2016</b> , 42, 932-941	2	5
30	Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150734	3.7	9
29	Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. <i>BMC Cancer</i> , <b>2016</b> , 16, 799	4.8	25
28	EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 176-82	3.3	15
27	Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. <i>European Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 84, 103-15	5.1	22
26	() Gene Variants: A Putative Cancer Stem Cell Marker in Risk Prediction of Bladder Cancer in North Indian Population. <i>Indian Journal of Clinical Biochemistry</i> , <b>2017</b> , 32, 74-83	2.2	11

## (2018-2017)

25	Genetic Variation in Gene and Its Association with Bladder Cancer Risk in North Indian Population. <i>Indian Journal of Clinical Biochemistry</i> , <b>2017</b> , 32, 292-300	2.2	2
24	EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification. <i>Medicine (United States)</i> , <b>2018</b> , 97, e12006	1.8	3
23	Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. <i>Scandinavian Journal of Immunology</i> , <b>2019</b> , 90, e12818	3.4	28
22	MicroRNA-3648 Is Upregulated to Suppress TCF21, Resulting in Promotion of Invasion and Metastasis of Human Bladder Cancer. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 16, 519-530	10.7	23
21	Association of human papilloma virus (HPV) infection with oncological outcomes in urothelial bladder cancer. <i>Infectious Agents and Cancer</i> , <b>2020</b> , 15, 52	3.5	8
20	Updates in Histologic Grading of Urologic Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 335-343	5	5
19	Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?. <i>BMJ Open</i> , <b>2021</b> , 11, e041894	3	2
18	Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 133, 111077	7.5	10
17	Major differences in glycosylation and Fucosyltransferase expression in low-grade versus high-grade bladder cancer cell lines. <i>Glycobiology</i> , <b>2021</b> ,	5.8	2
16	Chlorin-based photodynamic therapy enhances the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in bladder cancer cells. <i>Medical Science Monitor</i> , <b>2012</b> , 18, BR47-53	3.2	20
15	Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in Chinese population. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2019</b> , 71, 161-167	4.4	17
14	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2020</b> , 72, 1-12	4.4	7
13	High-grade urothelial bladder cancer in children: A case report and critical analysis of the literature. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia,</i> <b>2016</b> , 160, 578-582	1.7	5
12	Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2016</b> , 17, 381-6	1.7	83
11	Bladder Cancer. <b>2011</b> , 511-525		
10	Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significance. <i>Indian Journal of Pathology and Microbiology</i> , <b>2018</b> , 61, 526-53	10.6	1
9	Expression of HER2-neu, SKP2, and hypoxia-inducible factor-1 and their role in predicting the response of muscle-invasive urothelial carcinoma to bladder preservation chemotherapy. <i>Egyptian Journal of Pathology</i> , <b>2018</b> , 38, 61-67	O	
8	Value of CUB domain containing protein 1 expression in urothelial carcinoma. <i>Egyptian Journal of Pathology</i> , <b>2018</b> , 38, 92-96	Ο	

7	Correlation between aryl hydrocarbon receptor and IL-17 and Foxp3 T-cell infiltration in bladder cancer. <i>International Journal of Experimental Pathology</i> , <b>2021</b> , 102, 249-259	2.8	1
6	Scoping review: bladder cancer in Nigeria - what are the gaps in clinical care and research?. <i>BMJ Open</i> , <b>2022</b> , 12, e049241	3	
5	Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study. <i>Cancers</i> , <b>2022</b> , 14, 3135	6.6	0
4	Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases. <b>2022</b> , 14, 1909		3
3	STIL Promotes Tumorigenesis of Bladder Cancer by Activating PI3K/AKT/mTOR Signaling Pathway and Targeting C-Myc. <b>2022</b> , 14, 5777		0
2	Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. <b>2023</b> , 15, 1673		O
1	Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.		0